Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344880 | 1.00 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL2719765 | 0.83 | CRBN (0.54) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL24211424 | 0.80 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL3235862 | 0.80 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL24923587 | 0.80 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL2983403 | 0.80 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL20850213 | 0.77 | CRBN (0.47) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL22666465 | 0.77 | CRBN (0.47) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL9065010 | 0.77 | CRBN (0.47) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL21919776 | 0.76 | CRBN (0.46) | CRBNDDB1PKMPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212369-A1 | NUCLEOTIDE CYCLIC CLEAVABLE MOIETIES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4115908-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2020214763-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-7777024-B2 | Process for preparing a pentopyranosyl nucleic acid conjugate | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20090221793-A1 | PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE | SANOFI-AVENTIS S.A. (FR) | 2009-09-03 | — | — | US | disclosed |
| US-7501506-B2 | Pentopyranosyl nucleic acid conjugates | NANOGEN RECOGNOMICS GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| US-7153955-B2 | Pentopyranosyl nucleic acid arrays, and uses thereof | NANOGEN RECOGNOMICS GMBH (DE) | 2006-12-26 | — | — | US | disclosed |
| US-20060270840-A1 | Pentopyranosyl nucleic acid conjugates | SANOFI-AVENTIS S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| EP-1034180-B1 | LINKER NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | NANOGEN RECOGNOMICS GMBH (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-20050053945-A1 | Process for the preparation of a pentopyranosyl conjugate | NANOGEN RECOGNOMICS GMBH | 2005-03-10 | — | — | US | disclosed |
| EP-1070079-A2 | METHOD FOR THE PRODUCTION OF PENTOPYRANOSYL NUCLEOSIDES | Nanogen Recognomics GmbH (DE) | 2001-01-24 | — | — | EP | disclosed |
| EP-1034180-A2 | LINKER NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | Nanogen Recognomics GmbH (DE) | 2000-09-13 | — | — | EP | disclosed |
| EP-1019423-A2 | METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE | Nanogen Recognomics GmbH (DE) | 2000-07-19 | — | — | EP | disclosed |
| EP-1017704-A2 | USE OF A PENTOPYRANOSYL NUCLEOSIDE CONTAINING CONJUGATE FOR PRODUCING AN ARRAY | Nanogen Recognomics GmbH (DE) | 2000-07-12 | — | — | EP | disclosed |
| EP-1017703-A2 | PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | Nanogen Recognomics GmbH (DE) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999052923-A2 | METHOD FOR THE PRODUCTION OF PENTOPYRANOSYL NUCLEOSIDES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999015540-A2 | METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999015542-A2 | LINKER NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999015541-A2 | USE OF A PENTOPYRANOSYL NUCLEOSIDE FOR PRODUCING AN ELECTRONIC COMPONENT, AND CONJUGATES OF SAID PENTOPYRANOSYL NUCLEOSIDE | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999015539-A2 | PENTOPYRANOSYL NUCLEOSIDE, AND PRODUCTION AND USE OF THE SAME | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221793-A1 | PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE | RNGTT, NT5C3B, FUT6 | CRBN 1660/4885DDB1 350/4885PKM 2021/4885 |
| US-20050053945-A1 | Process for the preparation of a pentopyranosyl conjugate | FUT6, FUT5, FUCA2 | CRBN 3383/4885DDB1 3687/4885PKM 1264/4885 |
| US-20060270840-A1 | Pentopyranosyl nucleic acid conjugates | FUT6, RNGTT, B3GAT3 | CRBN 2361/4885DDB1 323/4885PKM 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.